CARMAT

Carmat will provide cardiologists with innovative technologies that save lives and improve the quality of life for patients with advanced heart failure... First implant of Aeson® within the framework of the EFICAS clinical study in France. This prospective study will involve a total of 52 patients eligible for a heart transplant in France and will allow CARMAT to collect both additional data on the efficacy and safety of its artificial heart and medico-economic data to support its value proposition and the device's reimbursement, notably in France. The study's primary endpoint is survival for 180 days after implantation of the device without a disabling stroke, or a successful heart transplant within 180 days of implantation... Carmat governance ensures an effective and transparent organization for its different supervisory and operational management teams to create long-term value for all stakeholders. It includes the Management Team and the Board of Directors.

Also known as: CARMAT SA

Primary location: Velizy-villacoublay France